HEB Hemispherx BioPharma Inc.

-0.01  -1%
Previous Close 1.9
Open 2
Price To Book 2.95
Market Cap 4,190,107
Shares 2,216,988
Volume 89,696
Short Ratio 1.16
Av. Daily Volume 196,767

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.
Phase 1 data due 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 data due 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 initiation of patient dosing announced June 12, 2019 with data due 2021.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence June 2019.
Ampligen, Intron A
Prostate Cancer

Latest News

  1. Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials
  2. Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?
  3. Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®
  4. Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing
  5. 5 Immunotherapy Stocks to Keep a Close Eye On
  6. Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com
  7. Hemispherx Biopharma CFO Adam Pascale Announces Retirement
  8. Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...
  9. Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?
  10. Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program
  11. Company News For Jun 13, 2019
  12. Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin
  13. Hemispherx Biopharma Stockholders Approve Reverse Stock Split
  14. Hemispherx Reports 2019 First Quarter Financial Results
  15. Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
  16. Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center
  17. Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology
  18. Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization
  19. Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress